• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension

Article

In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH).

In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.

This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.

Related Videos
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Sarah Bajorek, PhD, BCACP, MBA.
dr monica li
dr lawrence eichenfield
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.